FindTrial
Sign In

A possible regulatory network of lung-kidney qi deficiency syndrome in the stable phase of chronic obstructive pulmonary disease

Study on the mechanism of intervention of lung-kidney qi deficiency syndrome in COPD remission period by acupoint application based on lncRNA-miRNA-mRNA regulatory network for winter disease and summer treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001718
Enrollment
Unknown
Registered
2025-09-15
Start date
2022-08-29
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Lung-kidney qi deficiency syndrome in the remission period of COPD acupoint application group:Conventional Western medicine treatment+sanfu acupoint application
Lung-kidney qi deficiency syndrome in the remission period of COPD control group:Conventional Western medicine treatment+placebo acupoint application
Healthy control group:none
Non-lung-kidney qi deficiency syndrome in the remission period of COPD group:Conventional Western medicine treatment

Sponsors

Liaoning University of Traditional Chinese Medicine Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Group with lung-kidney qi deficiency syndrome during the remission period of COPD (1) It meets the Western medical diagnostic criteria for chronic obstructive pulmonary disease and is in the remission period; (2) Meet the diagnostic criteria for lung and kidney qi deficiency syndrome in traditional Chinese medicine; (3) Age: 45-80 years old; (4) The subjects were informed of this study and signed the informed consent form. 2. Other syndrome groups during the remission period of COPD (1) It meets the Western medical diagnostic criteria for chronic obstructive pulmonary disease and is in the remission period; (2) Other syndromes with non-lung-kidney qi deficiency syndrome; (3) Age: 45-80 years old; (4) Voluntarily become a subject and sign the informed consent form. 3. Healthy control group (1) Healthy subjects; (2) Age: 40-80 years old; (3) Voluntarily become a subject and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Those with concurrent pneumothorax pleural effusion lung cancer active pulmonary tuberculosis and other serious lung diseases; (2) Those with severe primary diseases such as cardiovascular and cerebrovascular diseases liver and kidney diseases and hematopoietic system diseases; (3) Patients with mental illness (4) Pregnant or lactating women; (5) Those with concurrent tumors congenital or acquired immune deficiencies; (6) Subjects with poor compliance.

Design outcomes

Primary

MeasureTime frame
Transcriptome sequencing;—

Countries

China

Contacts

Public ContactWang Linlin

Liaoning University of Traditional Chinese Medicine Affiliated Hospital

565133414@qq.com+86 195 6872 7835

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026